John Renger insider trades: Cerevel Therapeutics Holdings (CERE) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where John reports to the SEC
Open-market buys and sales
17 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 7, 2024 | CERE | ↓ Sell | 2,161 | $41.54 | $90K | Direct | Feb 8, 2024 (1d) |
| Nov 1, 2022 | CERE | ↓ Sell | 25,000 | $30.00 | $750K | Direct | Nov 3, 2022 (2d) |
| Oct 4, 2022 | CERE | ↓ Sell | 25,000 | $30.00 | $750K | Direct | Oct 6, 2022 (2d) |
| Aug 10, 2022 | CERE | ↓ Sell | 55,000 | $40.50 | $2.2M | Direct | Aug 12, 2022 (2d) |
| Aug 8, 2022 | CERE | ↓ Sell | 30,000 | $34.25 | $1.0M | Direct | Aug 9, 2022 (1d) |
| Jul 20, 2022 | CERE | ↓ Sell | 25,000 | $30.00 | $750K | Direct | Jul 22, 2022 (2d) |
| Jul 6, 2022 | CERE | ↓ Sell | 26,105 | $30.11 | $786K | Direct | Jul 7, 2022 (1d) |
| Apr 13, 2022 | CERE | ↓ Sell | 45,000 | $34.65 | $1.6M | Direct | Apr 15, 2022 (2d) |
| Mar 29, 2022 | CERE | ↓ Sell | 10,000 | $35.00 | $350K | Direct | Mar 31, 2022 (2d) |
| Mar 18, 2022 | CERE | ↓ Sell | 45,000 | $31.11 | $1.4M | Direct | Mar 18, 2022 (0d) |
| Mar 9, 2022 | CERE | ↓ Sell | 30,000 | $33.33 | $1.0M | Direct | Mar 11, 2022 (2d) |
| Mar 2, 2022 | CERE | ↓ Sell | 25,000 | $30.00 | $750K | Direct | Mar 4, 2022 (2d) |
| Feb 9, 2022 | CERE | ↓ Sell | 25,000 | $30.00 | $750K | Direct | Feb 11, 2022 (2d) |
| Dec 27, 2021 | CERE | ↓ Sell | 10,000 | $35.00 | $350K | Direct | Dec 28, 2021 (1d) |
| Dec 21, 2021 | CERE | ↓ Sell | 7,300 | $32.50 | $237K | Direct | Dec 23, 2021 (2d) |
| Dec 17, 2021 | CERE | ↓ Sell | 37,700 | $30.85 | $1.2M | Direct | Dec 17, 2021 (0d) |
| Nov 10, 2021 | CERE | ↓ Sell | 55,000 | $39.86 | $2.2M | Direct | Nov 15, 2021 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About John Renger's insider trades
John Renger is Chief Scientific Officer at Cerevel Therapeutics Holdings (CERE). Since Nov 10, 2021, John has reported no open-market purchases and 17 sales worth $16.1M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include option exercises (17 filings), grants and awards (5 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CERE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.